Cytogenetic Abnormalities In Acute Myeloid Leukaemia Patients

Mehwish Roshan Shaikh1, Ghulam Haider1, Paras Memon1

  • 1Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan.

Insights

Cytogenetic abnormalities were found in 37% of Acute myeloid leukaemia (AML) patients in Pakistan. Most patients (67%) had intermediate-risk cytogenetics, with complex abnormalities in 5 cases.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Acute myeloid leukaemia (AML) is a cancer of myeloid cells characterized by the abnormal proliferation of hematopoietic blasts.
  • Identifying cytogenetic abnormalities is crucial for understanding AML's heterogeneity and prognosis.

Purpose of the Study:

  • To determine the prevalence and types of cytogenetic abnormalities in Pakistani AML patients.
  • To classify these abnormalities into risk groups (favorable, intermediate, unfavorable).

Main Methods:

  • A cross-sectional study involving 92 AML patients (age 15-55) at a tertiary care hospital in Karachi, Pakistan.
  • Bone marrow biopsy analysis for cytogenetic abnormalities.
  • Classification of abnormalities into risk categories using SPSS 23.

Main Results:

  • Cytogenetic abnormalities were detected in 37% of AML patients; 63% had normal cytogenetics.
  • The majority of patients (67.4%) fell into the intermediate-risk group.
  • Complex cytogenetic abnormalities were the most frequent, found in 5 patients.

Conclusions:

  • Cytogenetic analysis is vital for AML patient prognosis, revealing abnormalities in 37% of cases in this cohort.
  • The observed frequency of cytogenetic abnormalities in this Pakistani population is lower than reported in international literature.
  • The predominance of intermediate-risk cytogenetic abnormalities highlights the need for tailored treatment strategies.
Abstract